The Reconstruction of Zimmer
Executive Summary
Long the market leader in orthopedics, Zimmer has seen itself leap-frogged by companies formed out of the recent wave of consolidation in the orthopedic industry. Free of its long-time pharmaceutical parent, Bristol-Myers Squibb, through the largest spin-off in health care history, Zimmer is looking to capitalize on its independence to get into high growth market segments the company was previously precluded from entering, such as spine and biologicals. Despite not being a player in the fastest-growing segments of orthopedics, spine and sports medicine, Zimmer has been consistently producing outstanding financial results, benefiting in part from investors' current strong support of orthopedics as a whole. In this interview, Zimmer's chairman and CEO, J. Raymond Elliott discusses how the company plans to utilize innovative approaches including direct-to-consumer advertising and minimally-invasive techniques and devices to drive Zimmer back to prominence.
You may also be interested in...
Navigating Ortho's Choppy Seas: An Interview with Zimmer's David Dvorak
Since becoming CEO of orthopedics giant Zimmer two years ago, David Dvorak has faced a host of challenges unprecedented in this booming market, including a federal investigation into and settlement of questionable relationships with customers and the most severe economic crisis in 30 years. But Dvorak seems calm and confident as he looks ahead.
Navigating Ortho's Choppy Seas: An Interview with Zimmer's David Dvorak
Since becoming CEO of orthopedics giant Zimmer two years ago, David Dvorak has faced a host of challenges unprecedented in this booming market, including a federal investigation into and settlement of questionable relationships with customers and the most severe economic crisis in 30 years. But Dvorak seems calm and confident as he looks ahead.
Orthopedics Through a Keyhole
Across a wide range of specialties, the unique features of minimally invasive surgery provides a consistent array of beneifts to patients, and orthopedic surgeons have worked hard over the past several years to reduce the size of incisions in hip and knee replacement. Skeptics argue that, given the extremely high success rates of conventional hip and knee replacement surgery, any movement toward MIS should be slow and should look beyond patient appeal to focus on long-term results. For MIS leader Zimmer, the bet on the new technique is a big one. The widespread adoption of MIS in orthopedics is less about the transformation of a procedure than about the transformation of a company and an industry.